Daxxify vs Botox: What Head-to-Head and Placebo Trials Actually Show

Start with our pillar guide: Argireline vs Matrixyl: Mechanisms, Trials and Which to Use, or browse all Reviews & Comparisons articles.

The Daxxify vs Botox question comes down to formulation and the kind of evidence behind each product. Both are botulinum toxin type A products for glabellar lines. Daxxify uses an RTP004 peptide excipient, and units are not interchangeable between the two. In one Revance-affiliated Phase 2 trial, the studied Daxxify arm had a longer median response than the studied Botox arm (24 vs 19 weeks). Phase 3 tested Daxxify only against placebo. Evidence: Limited (Phase 2 only).

Daxxify vs Botox in one minute

Evidence: Moderate for product identity; Limited for any superiority language.

• What they are: Daxxify (daxibotulinumtoxinA-lanm) and Botox Cosmetic (onabotulinumtoxinA) are both botulinum toxin type A products. Both are used for temporary improvement of moderate to severe glabellar (frown) lines.
• How they differ: The products are formulated differently, and labels say their units cannot be swapped one for one.
• What has been compared directly: One Phase 2 trial included both products[^1][^2]. The Phase 3 program compared Daxxify only with placebo[^3][^4].
• Who funded the research: Most of the Daxxify literature was funded or authored by Revance, the company that makes it.

Which product fits your face, history and goals is a decision to make with your clinician. This page does not recommend doses or regimens.

Same toxin class, different formulations

Evidence: Moderate (product identity verified against labels).

Botox Cosmetic's label describes onabotulinumtoxinA as a toxin complex formulated with human albumin. Daxxify's label describes daxibotulinumtoxinA-lanm as the 150 kDa toxin stabilized by a proprietary peptide excipient called RTP004, with no accessory proteins.

A Revance-authored overview describes Daxxify as the first botulinum toxin type A formulated with the stabilizing peptide RTP004 in place of human serum albumin. The overview also proposes that the peptide enhances binding to the surface of nerve cells[^8]. Its authors include Revance employees and stockholders, along with investigators for Revance. A more recent in vitro and in silico study reported that RTP004 binds the toxin and increases cell-surface binding and cleavage of SNAP-25, the protein the toxin targets[^13]. Revance funded that study, and all listed authors are current or former Revance employees.

These findings explain why the peptide is part of the conversation. They are still lab results and hypotheses. Research suggests a plausible mechanism, but the lab data do not show that the peptide makes Daxxify clinically superior in people. A formulation difference is a fact about the vial, not a ranking of products.

Is there a Daxxify vs Botox head-to-head trial?

Evidence: Limited (Phase 2 only).

Yes, there is one. A Phase 2 randomized, double-blind, dose-ranging study (NCT02303002) enrolled 268 adults with moderate or severe glabellar lines[^1]. Participants were randomized to one of three daxibotulinumtoxinA doses, a single onabotulinumtoxinA dose, or placebo, and were followed for at least 24 weeks. The authors carried Revance Clinical Development affiliations. The PubMed record lists no conflict-of-interest statement, so we flag the affiliations rather than treat the field as "none."

What the abstract reports:

• The two higher Daxxify doses had higher response rates in that study than the onabotulinumtoxinA arm on several efficacy outcomes. The trial also had a placebo arm, and the authors state it was not powered for comparisons between the active products, so these differences don't show that one product outperforms the other.
• The middle Daxxify dose had a significantly greater response rate and a longer median duration of response than the onabotulinumtoxinA arm: 24 vs 19 weeks (p=.030).
• The authors described that middle dose as having the most favorable risk-benefit balance.

A follow-up analysis of the same trial looked at efficacy and safety by baseline severity. It repeated the 24-week median duration against the onabotulinumtoxinA arm[^2]. Its authors also carried Revance affiliations.

Three caveats matter here. First, a Phase 2 dose-finding study is designed to choose doses, not to settle which product is superior. Second, the comparison covers only the specific doses studied, and units differ between products, so "more units" does not mean "more toxin." Third, the trial was sponsored by the manufacturer of the product that came out ahead. In the PubMed abstracts we reviewed, we found no Phase 3 trial comparing Daxxify with onabotulinumtoxinA for glabellar lines.

What did Phase 3 Daxxify trials measure (vs placebo)?

Evidence: Moderate vs placebo; not a comparison with Botox.

SAKURA 1 and 2 were Phase 3 double-blind, placebo-controlled trials with 609 participants (405 Daxxify, 204 placebo)[^3]. The primary outcome was a composite: at least a 2-point improvement at week 4, rated by both the investigator and the participant. This outcome significantly favored Daxxify. In line with the label, about 74% of Daxxify participants and about 1% or less of placebo participants met it. Participants were followed for at least 24 weeks and until their lines returned to baseline, up to 36 weeks. Revance employees co-authored the report.

A pooled report focused on duration came to the same conclusion: Daxxify was more effective than placebo[^4]. Its discussion contrasted the prolonged duration with historical expectations for onabotulinumtoxinA. That contrast is with historical expectations from other studies, not with a Botox arm in the same trial, so it is not head-to-head evidence. The authors have Revance affiliations.

SAKURA 3 was an open-label repeat-treatment study with 2,691 participants[^5][^6]:

• More than 96% of participants were rated none or mild on the investigator's frown-line scale after each of up to three treatments.
• Peak effect came at weeks 2–4.
• At week 24, at least 32% were still none or mild after the first treatment[^5].
• The safety report covered 882 second treatments and 568 third treatments. Treatment-related adverse events occurred in 17.8% of participants[^6].

The authors of both reports were Revance employees and investigators, and the safety report notes that the Revance employees hold stock options. Because the study was open-label, everyone knew they were receiving the active product.

Three further analyses add context:

• Static lines: A post hoc analysis of 568 participants who received three treatments reported improvement in lines visible at rest. The share rated "none" rose from 9.0% (participant-rated) and 27.3% (investigator-rated) at baseline to 57.9% and 64.8% four weeks after the first cycle[^7]. The authors have Revance affiliations.
• Age and race: A Revance-funded subgroup analysis with Revance employee authors looked at outcomes by age and race after the first treatment[^12].
• China: A Phase 3 placebo-controlled trial in China used a similar week-4 composite endpoint and 24–36 weeks of follow-up[^11]. It suggests the results may hold in another population, but it did not include onabotulinumtoxinA. PubMed lists no funding or COI information for this trial. We record that as missing, not as "none."

Some secondary sources use phrases like "lasts about 6 months." A narrative overview cites a median duration of about six months, with some patients reaching about nine months, drawn from SAKURA program language[^14]. Its author discloses serving as a SAKURA investigator and advisor for Revance. The program followed patients for at least 24 weeks, but individual results vary, and no duration should be promised to any reader.

How does Daxxify vs Botox duration compare with typical Botox evidence?

Evidence: Cross-reference (see companion page).

The Botox Cosmetic label describes glabellar effects lasting up to about 120 days, and pooled Botox analyses report median figures in a similar range. Most of that literature is tied to Allergan/AbbVie. We cover it in detail, including crow's feet and forehead lines, on our companion page, how long does Botox last. Comparing Daxxify's SAKURA results with numbers from separate Botox trials is not the same as a randomized head-to-head comparison. The trials differ in populations, endpoints and definitions of duration.

Does the Daxxify peptide affect immunogenicity?

Evidence: Limited–moderate.

Any protein-based injectable can trigger antibodies, so regulators expect manufacturers to check for them. A pooled SAKURA analysis found treatment-related binding antibodies against daxibotulinumtoxinA in 21 of 2,737 participants (0.8%). No neutralizing antibodies were detected, and binding antibodies against RTP004 occurred at low rates[^9]. A second analysis reported the same pattern: 0.8% treatment-related anti-Daxxify binding antibodies, 1.3% treatment-related anti-RTP004 binding antibodies among evaluable exposed participants, and no neutralizing antibodies[^10]. Revance funded both analyses and also funded the writing support for the second (per its full text).

It is best to read these results as routine safety monitoring rather than a warning or a selling point. Binding antibodies are not the same as neutralizing antibodies, which are the type that could reduce effect. Data on long-term, many-cycle use remain limited.

FDA approvals and indication scope

Evidence: Verified against database and label (recheck on publish day).

• Daxxify: FDA approved it for glabellar lines on 2022-09-07 under BLA761127. A supplement for cervical dystonia, a neurological condition, was approved on 2023-08-11. That is a medical use, not an aesthetic one. In our label check, Daxxify's US aesthetic indication is limited to glabellar lines. Forehead, crow's feet and perioral uses were not the basis of the 2022 approval.
• Botox Cosmetic: Its aesthetic label covers several areas (glabellar lines, crow's feet, forehead lines and platysma bands), each added through dated supplements. Details are on the duration page.
• Units: Units are specific to each product and cannot be converted between them. We do not publish conversion ratios or dosing. Ask your clinician.

If you have read about neuromodulators for a "lip flip" (lip flip ), note that Daxxify is not FDA-approved for that area. A Revance-supported post hoc analysis looked at brow position and frontalis strain after glabellar Daxxify treatment[^15]. It is context for our planned piece on Botox brow lift , not a brow-lift efficacy trial. For related wrinkle areas, see our guides to bunny lines and forehead wrinkles.

Who paid for the Daxxify vs Botox evidence?

Evidence: Transparency note.

Several investigators in the Daxxify studies also consult for or run trials for Allergan/AbbVie, as disclosed in the full texts of the immunogenicity, subgroup and brow-position papers[^10][^12][^15]. That is a conflict of interest worth knowing about. It does not mean Allergan funded the Daxxify trials. Ipsen and Galderma (Dysport) did not sponsor any of the trials discussed here; their products belong on the Dysport vs Botox hub .

For aftercare, including when to restart retinoids, see tretinoin after Botox and skincare after Botox. We found no evidence that tretinoin changes how long either Daxxify or Botox lasts.

Where the evidence stops

• No Phase 3 head-to-head: In the abstracts we reviewed, we found no Phase 3 trial comparing Daxxify with onabotulinumtoxinA for glabellar lines. The only direct comparison is a manufacturer-affiliated Phase 2 study that was not powered for that contrast.
• The peptide is not a ranking: RTP004 is a formulation fact supported by lab mechanism data. Neither shows that Daxxify is clinically superior.
• Duration figures describe groups: Medians and week-24 percentages describe trial groups, not what you will personally experience.
• Most evidence comes from the manufacturers: Nearly all Daxxify data are Revance-funded or Revance-authored. Botox duration data are largely tied to Allergan/AbbVie.
• Off-label areas: In the sources reviewed, use outside the glabellar area is not supported by Daxxify's US aesthetic label.
• Units do not convert: Doses cannot be translated between products. Ask your clinician.

FAQ

References

[^1]: Phase 2 randomized, double-blind, dose-ranging trial of daxibotulinumtoxinA vs onabotulinumtoxinA and placebo for glabellar lines (n=268). PubMed: 28614091. Funding/COI: Revance Clinical Development affiliations; PubMed COI statement blank. [^2]: Additional Phase 2 analyses by baseline severity from the same head-to-head trial. PubMed: 33065952. Funding/COI: Revance affiliations. [^3]: SAKURA 1 and 2 Phase 3 double-blind, placebo-controlled trials of daxibotulinumtoxinA for glabellar lines (n=609). PubMed: 31609882. Funding/COI: Revance co-authors. [^4]: Pooled SAKURA 1/2 duration-focused report. PubMed: 31791824. Funding/COI: Revance affiliations. [^5]: SAKURA 3 open-label repeat-treatment efficacy study (n=2,691). PubMed: 32773446. Funding/COI: Revance employees and investigators. [^6]: SAKURA 3 open-label safety report. PubMed: 32773447. Funding/COI: Revance employees hold stock options. [^7]: Post hoc SAKURA analysis of static glabellar lines after repeat treatment (n=568). PubMed: 34417396. Funding/COI: Revance affiliations. [^8]: Overview of daxibotulinumtoxinA formulation with RTP004 peptide. PubMed: 34787840. Funding/COI: Revance employees/stockholders among authors; investigators for Revance. [^9]: Pooled SAKURA immunogenicity analysis. PubMed: 36668880. Funding/COI: Revance-funded. [^10]: Immunogenicity analysis of anti-daxibotulinumtoxinA and anti-RTP004 antibodies. PubMed: 37051886. Funding/COI: Revance-funded, including writing support; some investigators disclose Allergan/AbbVie consulting (full text). [^11]: China Phase 3 double-blind, placebo-controlled trial of daxibotulinumtoxinA for glabellar lines. PubMed: 39353286. Funding/COI: Not stated in PubMed (missing, not none). [^12]: SAKURA subgroup analysis by age and race. PubMed: 36087303. Funding/COI: Revance-funded; Revance employee authors; some investigators disclose Allergan/AbbVie consulting (full text). [^13]: In vitro and in silico study of RTP004 binding to BoNT/A1 and cell-surface binding. PubMed: 41893557. Funding/COI: Revance-funded; all listed authors current or former Revance employees. [^14]: Narrative overview of daxibotulinumtoxinA following FDA approval. PubMed: 37440610. Funding/COI: Author discloses SAKURA investigator/advisor role for Revance. [^15]: Post hoc analysis of brow position and frontalis strain after glabellar daxibotulinumtoxinA. PubMed: 36095026. Funding/COI: Revance-supported; some investigators disclose Allergan/AbbVie consulting (full text).

For educational purposes only; not medical advice. See our disclaimer and research method.